Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Vaxcyte | 2026 | Post Ipo Equity | $632.5M | San Carlos |
| bit.bio | 2026 | Series C | $50.0M | Cambridge |
| Alumis | 2026 | Post Ipo Equity | $345.1M | San Francisco |
| Aeovian Pharmaceuticals | 2025 | Series B | $55.0M | San Francisco |
| Myome | 2025 | Series Unknown | Undisclosed | Palo Alto |
| Wave Life Sciences | 2025 | Post Ipo Equity | $350.0M | Boston |
| Invivyd | 2025 | Post Ipo Equity | $125.0M | Waltham |
| Indomo | 2025 | Seed | $25.0M | San Francisco |
| Tango Therapeutics | 2025 | Post Ipo Equity | $197.0M | Cambridge |
| Nurix Therapeutics | 2025 | Post Ipo Equity | $250.0M | San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Vaxcyte | Post Ipo Equity | $632.5M | San Carlos, United States |
| 27 | bit.bio | Series C | $50.0M | Cambridge, United Kingdom |
| 28 | Alumis | Post Ipo Equity | $345.1M | San Francisco, United States |
| 29 | Aeovian Pharmaceuticals | Series B | $55.0M | San Francisco, United States |
| 30 | Myome | Series Unknown | Undisclosed | Palo Alto, United States |
| 31 | Wave Life Sciences | Post Ipo Equity | $350.0M | Boston, United States |
| 32 | Invivyd | Post Ipo Equity | $125.0M | Waltham, United States |
| 33 | Indomo | Seed | $25.0M | San Francisco, United States |
| 34 | Tango Therapeutics | Post Ipo Equity | $197.0M | Cambridge, United States |
| 35 | Nurix Therapeutics | Post Ipo Equity | $250.0M | San Francisco, United States |
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development.
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Myome helps identify genes that cause disease and act based on leading science.
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Indomo is a clinical-stage firm that aims to improve access to quality healthcare through novel device-enabled treatments.
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.
Thyme Care is a healthcare company that provides oncology care management services.
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.
Quantum SI offers Next Generation Protein Sequencing that makes diagnostics digital.
RayThera is dedicated to developing small molecule therapies specifically targeting unmet needs in immunology.
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Abcuro develops immunotherapies to treat autoimmunity and cancer.
Sollis Health offers concierge medical centers that provide on-demand care for families, including same-day visits and virtual care options.
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Foresite Capital has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Foresite Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 18 different industry categories.
Among tracked funding rounds, Vaxcyte received $632.5M in a Post Ipo Equity round. Foresite Capital's total known invested capital is $8.3B.
Foresite Capital's average investment size is $127.9M across its portfolio of 81 companies.
Recent Foresite Capital portfolio additions include Vaxcyte, bit.bio, Alumis, Aeovian Pharmaceuticals, Myome. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors